stock research tool
Are These The 6 Best Stocks In The Dow Jones Industrial Average? – Part 3 Of 5
2017-10-13
Introduction In Part 1 and Part 2 of this series I covered 12 of the 30 Dow Jones Industrial Average stocks that I considered the most expensive of the index. With this part 3 I will be looking at 6 additional Dow stocks that for the most part I would consider fully valued to only […]
My Visa Long is Getting Long in the Tooth
2017-09-14
Introduction Over my lifetime I have invested in many different things. In the process of doing that, I have learned that there are really only two types of investors. As an investor, you are either active or passive. Being active implies directly managing or being in control of your investment. In contrast, as a passive […]
FAST Graphs Forecasting – What it is and How it Works
2017-09-01
The Five Forecasting Calculators on FAST Graphs – This video will illustrate how to correctly utilize the Forecasting Calculators.
The Active versus Passive Performance Debate Is Nonsensical
2017-05-18
Research Articles, Uncategorized
Introduction One of the most hotly contested debates in finance is the argument over which is better – active or passive investing. Moreover, this debate has spurred numerous academic studies that claim to identify whether passive outperforms active investing or vice versa. As a result, the current popular opinion suggests that passive outperforms active investing […]
5 Fairly Valued MLPs: Is the Dilution Worth the Yield and How Do You Value Them?
2017-02-22
Introduction The 5 MLPs covered in this article offer yields ranging from 5.7% to 10.7%. Additionally, each of these MLPs appears reasonably valued given their high yields and prospects for growth. However, two of these MLPs are currently in the process of merging. MLPs Simple and Complex at the Same Time I believe that MLPs […]
Pfizer Inc. Invest For Attractive Valuation and The 4% Dividend Yield
2017-02-22
Investment Thesis Pfizer Inc (PFE) is one of the world’s largest pharmaceutical firms with sales exceeding $50 billion. The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%. Pfizer is awarded an S&P credit rating of AA and possesses a modest debt to capital ratio […]